Top

Digestive Diseases and Sciences

Published in:

01-08-2016 | Original Article

Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study

Authors: Ali Riza Koksal, Salih Boga, Huseyin Alkim, Mehmet Bayram, Meltem Ergun, Canan Alkim

Published in: Digestive Diseases and Sciences | Issue 8/2016

Abstract

Background and Aims

The relationship between insulin resistance and post-ERCP pancreatitis (PEP) is not known. We aimed to determine the relation between pre-ERCP insulin resistance and risk of PEP, and to evaluate the relationship of insulin resistance with well-established risk factors for PEP.

Methods

Consecutive patients who underwent ERCP with the diagnosis of choledocolithiasis between January and December 2013 were enrolled in this prospective study. Pre-procedural insulin resistance state and other risk factors were evaluated according to PEP development.

Results

Pancreatitis developed in 16 (11.3 %) of 141 ERCP procedure. Homeostasis model assessment of insulin resistance (HOMA-IR) levels was found statistically significantly higher in patients who developed PEP than the ones who did not (3.37 ± 0.8 vs. 2.38 ± 1.4, p < 0.001). Common bile duct (CBD) diameter of the patients developing PEP was found significantly lower than the non-PEP group (10.1 ± 4 vs. 13.4 ± 4.5 mm, p = 0.01). Mean procedure time was 33.5 min in PEP group and 27.9 min in non-PEP group (p = 0.006). HOMA-IR (OR 2.39), procedure time (OR 1.15), and CBD diameter (OR 0.82) were independent predictors of PEP development.

Conclusions

The presence of insulin resistance is an important risk factor for PEP, and these data can be used as a considerable clue to predict the risk of PEP before ERCP and to decrease related morbidity.

Freeman ML. Post-ERCP pancreatitis: patient and technique-related risk factors. JOP J Pancreas. 2002;3:169–176.

Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc. 1998;48:1–10.CrossRefPubMed

Dickinson RJ, Davies S. Post-ERCP pancreatitis and hyperamylasaemia: the role of operative and patient factors. Eur J Gastroenterol Hepatol. 1998;10:423–428.CrossRefPubMed

Wang P, Li Z-S, Liu F, et al. Risk factors for ERCP-related complications: a prospective multicenter study. Am J Gastroenterol. 2009;104:31–40.CrossRefPubMed

Cotton PB, Garrow DA, Gallagher J, et al. Risk factors for complications after ERCP: a multivariate analysis of 11,497 procedures over 12 years. Gastrointest Endosc. 2009;70:80–88.CrossRefPubMed

Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol. 2001;96:417–423.CrossRefPubMed

Christoforidis E, Goulimaris I, Kanellos I, et al. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy. 2002;34:286–292.CrossRefPubMed

Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.CrossRefPubMed

Thaker AM, Mosko JD, Berzin TM. Post-endoscopic retrograde cholangiopancreatography pancreatitis. Gastroenterol Rep. 2015;3:32–40.CrossRef

10.

Chen J-J, Wang X-M, Liu X-Q, et al. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years. Eur J Med Res. 2014;19:26.CrossRefPubMedPubMedCentral

11.

Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc. 2001;54:425–434.CrossRefPubMed

12.

Badalov N, Tenner S, Baillie J. The Prevention, recognition and treatment of post-ERCP pancreatitis. JOP J Pancreas. 2009;10:88–97.

13.

Sahakian AB, Buxbaum JL, Van Dam J. Prevention and management of Post-ERCP Pancreatitis. JOP J Pancreas. 2014;15:544–551.

14.

Testoni PA. Unresolved issues about post-ERCP pancreatitis: an overview. JOP J Pancreas. 2002;3:156–161.

15.

Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms involved in the onset of post-ERCP pancreatitis. JOP J Pancreas. 2002;3:162–168.

16.

Ito K, Fujita N, Noda Y, et al. Relationship between post-ERCP pancreatitis and the change of serum amylase level after the procedure. World J Gastroenterol. 2007;13:3855–3860.CrossRefPubMedPubMedCentral

17.

Messmann H, Vogt W, Holstege A, et al. Post-ERP pancreatitis as a model for cytokine induced acute phase response in acute pancreatitis. Gut. 1997;40:80–85.CrossRefPubMedPubMedCentral

18.

Leung PS, Chan YC. Role of oxidative stress in pancreatic inflammation. Antioxid Redox Signal. 2009;11:135–165.CrossRefPubMed

19.

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428.CrossRefPubMed

20.

Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol. 2013;218:R25–R36.CrossRefPubMed

21.

Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640–1645.CrossRefPubMed

22.

Aroor AR, McKarns S, Demarco VG, et al. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62:1543–1552.CrossRefPubMed

23.

Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168:1609–1616.CrossRefPubMed

24.

Apovian CM, Bigornia S, Mott M, et al. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc Biol. 2008;28:1654–1659.CrossRefPubMedPubMedCentral

25.

Ozkul A, Ayhan M, Akyol A, et al. The effect of insulin resistance on inflammatory response and oxidative stress in acute cerebral ischemia. Neuro Endocrinol Lett. 2013;34:52–57.PubMed

26.

Caccamo G, Bonura F, Bonura F, et al. Insulin resistance and acute coronary syndrome. Atherosclerosis. 2010;211:672–675.CrossRefPubMed

27.

Frossard J-L, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. World J Gastroenterol. 2009;15:5260–5265.CrossRefPubMedPubMedCentral

28.

Deenadayalu VP, Blaut U, Watkins JL, et al. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis? A retrospective, multicenter study. J Clin Gastroenterol. 2008;42:1103–1109.CrossRefPubMed

29.

Pokhrel B, Choi EK, Khalid O, et al. Increased fat in pancreas not associated with risk of pancreatitis post-endoscopic retrograde cholangiopancreatography. Clin Exp Gastroenterol. 2014;7:199–204.PubMedPubMedCentral

30.

Iorgulescu A, Sandu I, Turcu F, Iordache N. Post-ERCP acute pancreatitis and its risk factors. J Med Life. 2013;6:109–113.PubMedPubMedCentral

31.

Testoni PA, Mariani A, Giussani A, et al. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol. 2010;105:1753–1761.CrossRefPubMed

32.

Katsinelos P, Lazaraki G, Chatzimavroudis G, et al. Risk factors for therapeutic ERCP-related complications: an analysis of 2,715 cases performed by a single endoscopist. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2014;27:65–72.

33.

Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. J Pancreas. 2002;3:195–201.

34.

Hernández Garcés HR, Almeida Linnet A, Abreu Vázquez MDR, et al. Risk factors associated with the development of hyperamylasemia and post-ERCP pancreatitis in the Cuban National Institute. Rev Gastroenterol Perú Órgano Soc Gastroenterol Perú. 2014;34:127–132.

35.

Leghari A, Ghazanfar S, Qureshi S, et al. Frequency and risk factors in the post-ERCP pancreatitis in a tertiary care centre. J Coll Phys Surg Pak. 2013;23:620–624.

36.

Jacobson BC, Carr-Locke DL. Hypotension during ERCP is common but not a risk factor for post-ERCP pancreatitis. HPB. 2001;3:169–173.CrossRefPubMedPubMedCentral

37.

Beyazit Y, Sayilir A, Torun S, et al. Mean platelet volume as an indicator of disease severity in patients with acute pancreatitis. Clin Res Hepatol Gastroenterol. 2012;36:162–168.CrossRefPubMed

38.

Nakai Y, Isayama H, Sasahira N, et al. Risk factors for post-ERCP pancreatitis in wire-guided cannulation for therapeutic biliary ERCP. Gastrointest Endosc. 2015;81:119–126.CrossRefPubMed

39.

Yashima Y, Isayama H, Tsujino T, et al. A large volume of visceral adipose tissue leads to severe acute pancreatitis. J Gastroenterol. 2011;46:1213–1218.CrossRefPubMed

40.

Oskarsson V, Sadr-Azodi O, Orsini N, et al. High dietary glycemic load increases the risk of non-gallstone-related acute pancreatitis: a prospective cohort study. Clin Gastroenterol Hepatol. 2014;12:676–682.CrossRefPubMed

41.

Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834–838.CrossRefPubMedPubMedCentral

42.

Brochu M, Starling RD, Tchernof A, et al. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J Clin Endocrinol Metab. 2000;85:2378–2384.PubMed

43.

Tulloch-Reid MK, Hanson RL, Sebring NG, et al. Both subcutaneous and visceral adipose tissue correlate highly with insulin resistance in african americans. Obes Res. 2004;12:1352–1359.CrossRefPubMed

44.

Kumar N, Gergi MA, Thompson CC. Obesity is an independent risk factor for post-ERCP pancreatitis: results of a nationwide database analysis [Abstract]. Gastrointest Endosc. 2012;75:AB142.

45.

Johnson GK, Geenen JE, Johanson JF, et al. Evaluation of post-ERCP pancreatitis: potential causes noted during controlled study of differing contrast media. Midwest Pancreaticobiliary Study Group. Gastrointest Endosc. 1997;46:217–222.CrossRefPubMed

46.

Cennamo V, Fuccio L, Zagari RM, et al. Can early precut implementation reduce endoscopic retrograde cholangiopancreatography-related complication risk? Meta-analysis of randomized controlled trials. Endoscopy. 2010;42:381–388.CrossRefPubMed

47.

Mehta PP, Sanaka MR, Parsi MA, et al. Association of procedure length on outcomes and adverse events of endoscopic retrograde cholangiopancreatography. Gastroenterol Rep. 2014;2:140–144.CrossRef

48.

Technology Committee ASGE, Kethu SR, Adler DG, Diehl DL, et al. ERCP cannulation and sphincterotomy devices. Gastrointest Endosc. 2010;71:435–445.CrossRef

Title: Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study
Authors: Ali Riza Koksal
Salih Boga
Huseyin Alkim
Mehmet Bayram
Meltem Ergun
Canan Alkim
Publication date: 01-08-2016
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 8/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-016-4127-0

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Insulin Resistance as a Novel Risk Factor for Post-ERCP Pancreatitis: A Pilot Study

Abstract

Background and Aims

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background and Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2016

DDS Elementary Style: A Brief Guide for Authors

Potential Role of the Microbiome in Barrett’s Esophagus and Esophageal Adenocarcinoma

Treatment of Dual Genotype Chronic Hepatitis C: Case Series

Co-lyophilized Aspirin with Trehalose Causes Less Injury to Human Gastric Cells and Gastric Mucosa of Rats

Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome

GI-Safer Aspirin: Sometimes Sugar Coating Helps

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page